Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of Anti-GD2 Chimeric Antigen Receptor-Expressing T Cells in Pediatric and Young Adult Patients Affected by Relapsed/Refractory Central Nervous System Tumors

NCT05298995 is registered in ClinicalTrials.gov with Bambino Gesù Hospital and Research Institute as lead sponsor.

NCT NCT05298995
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05298995 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of Anti-GD2 Chimeric Antigen Receptor-Expressing T Cells in Pediatric and Young Adult Patients Affected by Relapsed/Refractory Central Nervous System Tumors
Lead sponsor
Bambino Gesù Hospital and Research Institute
Phase
Phase 1
Overall status
Recruiting
Start date
November 9, 2023
Completion date
November 30, 2038
Enrollment
54 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

brain tumor adult, brain tumor, pediatric, diffuse intrinsic pontine glioma, diffuse midline glioma, embryonal tumor, high grade glioma, medulloblastoma, childhood